Self-inactivating MLV Vectors Have a Reduced Genotoxic Profile in Human Epidermal Keratinocytes
Overview
Affiliations
Transplantation of epithelia derived from keratinocyte stem cells transduced by retroviral vectors is a potential therapy for epidermolysis bullosa (EB), a family of inherited skin adhesion defects. The biosafety characteristics of retroviral vectors in keratinocytes are, however, poorly defined. We developed self-inactivating (SIN) vectors derived from the Moloney murine leukemia (MLV) and the human immunodeficiency (HIV) viruses expressing therapeutic levels of LAMB3, a transgene defective in junctional EB, and tested their integration profile in human primary keratinocytes. The SIN-HIV vector showed the expected preference for transcribed genes while the SIN-MLV vector integrated preferentially in regulatory elements, but showed a significantly lower tendency to target cell growth-related genes, transcription start sites and epigenetically defined promoters compared with a wild-type MLV vector in an epithelial cell context. A quantitative gene expression assay in individual keratinocyte clones showed that MLV-derived vectors deregulate expression of targeted genes at a lower frequency than in hematopoietic cells, and that the SIN-MLV design has the lowest activity compared to both MLV and SIN-HIV vectors. This study indicates that SIN-MLV vectors may have a better safety profile in keratinocyte than in hematopoietic cells, and be a reasonable alternative to lentiviral vectors for gene therapy of inherited skin disorders.
A cellular disease model toward gene therapy of -dependent lamellar ichthyosis.
Sercia L, Romano O, Marini G, Enzo E, Forcato M, De Rosa L Mol Ther Methods Clin Dev. 2024; 32(3):101311.
PMID: 39234443 PMC: 11372595. DOI: 10.1016/j.omtm.2024.101311.
Optimal delivery of RNA interference by viral vectors for cancer therapy.
Wong B, Birtch R, Rezaei R, Jamieson T, Crupi M, Diallo J Mol Ther. 2023; 31(11):3127-3145.
PMID: 37735876 PMC: 10638062. DOI: 10.1016/j.ymthe.2023.09.012.
De Rosa L, Enzo E, Zardi G, Bodemer C, Magnoni C, Schneider H Front Genet. 2021; 12:705019.
PMID: 34539738 PMC: 8440932. DOI: 10.3389/fgene.2021.705019.
Kurinna S, Seltmann K, Bachmann A, Schwendimann A, Thiagarajan L, Hennig P Nucleic Acids Res. 2021; 49(7):3748-3763.
PMID: 33764436 PMC: 8053124. DOI: 10.1093/nar/gkab167.
Delivery technologies for in utero gene therapy.
Palanki R, Peranteau W, Mitchell M Adv Drug Deliv Rev. 2020; 169:51-62.
PMID: 33181188 PMC: 7855052. DOI: 10.1016/j.addr.2020.11.002.